J
Jonathan W. Riess
Researcher at University of California, Davis
Publications - 163
Citations - 5745
Jonathan W. Riess is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 24, co-authored 117 publications receiving 3753 citations. Previous affiliations of Jonathan W. Riess include Stanford University & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
siRNA-directed inhibition of HIV-1 infection.
Carl D. Novina,Michael F. Murray,Derek M. Dykxhoorn,Paul J. Beresford,Jonathan W. Riess,Sang-Kyung Lee,Ronald G. Collman,Judy Lieberman,Premlata Shankar,Phillip A. Sharp +9 more
TL;DR: It is reported that siRNAs inhibit virus production by targeting the mRNAs for either the HIV-1 cellular receptor CD4, the viral structural Gag protein or green fluorescence protein substituted for the Nef regulatory protein.
Journal ArticleDOI
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo,Philip C. Mack,Giorgio V. Scagliotti,Paul Baas,Fabrice Barlesi,Trever G. Bivona,Roy S. Herbst,Tony Mok,Nir Peled,Robert Pirker,Luis E. Raez,Martin Reck,Jonathan W. Riess,Lecia V. Sequist,Frances A. Shepherd,Lynette M. Sholl,Daniel Shao-Weng Tan,Heather A. Wakelee,Ignacio I. Wistuba,Murry W. Wynes,David P. Carbone,Fred R. Hirsch,David R. Gandara +22 more
TL;DR: It is concluded that liquid biopsy approaches have significant potential to improve patient care, and immediate implementation in the clinic is justified in a number of therapeutic settings relevant to NSCLC.
Journal ArticleDOI
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely,Thomas B.K. Watkins,Wei Wu,Beatrice Gini,Jacob J. Chabon,Caroline E. McCoach,Nicholas McGranahan,Gareth A. Wilson,Nicolai Juul Birkbak,Victor Olivas,Julia K Rotow,Ashley Maynard,Victoria E. Wang,Matthew A. Gubens,Kimberly C. Banks,Richard B. Lanman,Aleah F. Caulin,John St. John,Anibal Cordero,Petros Giannikopoulos,Andrew Simmons,Philip C. Mack,David R. Gandara,Hatim Husain,Robert C. Doebele,Jonathan W. Riess,Maximilian Diehn,Charles Swanton,Trever G. Bivona +28 more
TL;DR: This study calls for revisiting the prevailing single-gene driver-oncogene view and links clinical outcomes to co-occurring genetic alterations in patients with advanced-stage EGFR-mutant lung cancer.
Journal ArticleDOI
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Ticiana A. Leal,Jonathan W. Riess,Erin Jensen,Bin Zhao,M. Catherine Pietanza,Julie R. Brahmer +18 more
TL;DR: The first 5-year follow-up of any first-line phase III immunotherapy trial for non-small-cell lung cancer (NSCLC) was reported in this article.
Journal ArticleDOI
A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors
Nadine Jahchan,Joel T. Dudley,Pawel K. Mazur,Natasha M. Flores,Dian Yang,Alec Palmerton,Anne-Flore Zmoos,Dedeepya Vaka,Kim Q.t. Tran,Margaret Zhou,Karolina Krasinska,Jonathan W. Riess,Joel W. Neal,Purvesh Khatri,Kwon S. Park,Atul J. Butte,Julien Sage +16 more
TL;DR: This work shows the power of bioinformatics-based drug approaches to rapidly repurpose FDA-approved drugs and identifies a novel class of molecules to treat patients with SCLC, a cancer for which no effective novel systemic treatments have been identified in several decades.